BidaskClub lowered shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a sell rating in a report released on Friday morning.

Several other brokerages also recently weighed in on NTLA. Oppenheimer reissued a hold rating on shares of Intellia Therapeutics in a research note on Tuesday. Barclays reissued a buy rating on shares of Intellia Therapeutics in a research note on Sunday, November 5th. Credit Suisse Group boosted their target price on shares of Intellia Therapeutics from $24.00 to $28.00 and gave the company an outperform rating in a research note on Friday, November 3rd. Jefferies Group reissued a buy rating and issued a $36.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, October 3rd. Finally, Zacks Investment Research raised shares of Intellia Therapeutics from a sell rating to a hold rating in a research note on Wednesday, October 4th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $30.17.

Shares of Intellia Therapeutics (NASDAQ NTLA) traded up $0.98 during mid-day trading on Friday, reaching $18.37. 2,734,136 shares of the company traded hands, compared to its average volume of 808,440. Intellia Therapeutics has a 12-month low of $10.83 and a 12-month high of $33.34.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Tuesday, October 31st. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.06. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. The firm had revenue of $7.30 million during the quarter, compared to the consensus estimate of $5.83 million. During the same quarter in the previous year, the company posted ($0.22) EPS. The firm’s revenue for the quarter was up 49.0% on a year-over-year basis. equities analysts expect that Intellia Therapeutics will post -1.68 earnings per share for the current fiscal year.

In related news, CEO Nessan Bermingham sold 111,500 shares of the stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $20.34, for a total transaction of $2,267,910.00. Following the completion of the sale, the chief executive officer now owns 696,000 shares of the company’s stock, valued at approximately $14,156,640. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $18.30, for a total transaction of $27,870,900.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,971,283 shares of company stock valued at $37,137,161. Corporate insiders own 12.80% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GMT Capital Corp purchased a new position in Intellia Therapeutics in the 3rd quarter worth approximately $8,214,000. Neuberger Berman Group LLC boosted its holdings in Intellia Therapeutics by 14.9% in the 2nd quarter. Neuberger Berman Group LLC now owns 49,517 shares of the company’s stock worth $792,000 after acquiring an additional 6,431 shares during the period. American Century Companies Inc. purchased a new position in Intellia Therapeutics in the 2nd quarter worth approximately $583,000. Wells Fargo & Company MN boosted its holdings in Intellia Therapeutics by 176.1% in the 2nd quarter. Wells Fargo & Company MN now owns 30,215 shares of the company’s stock worth $483,000 after acquiring an additional 19,270 shares during the period. Finally, Bank of Montreal Can boosted its holdings in Intellia Therapeutics by 1,031.7% in the 2nd quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock worth $127,000 after acquiring an additional 7,222 shares during the period. Hedge funds and other institutional investors own 49.55% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Intellia Therapeutics (NTLA) Downgraded by BidaskClub to Sell” was published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/12/16/intellia-therapeutics-ntla-downgraded-by-bidaskclub-to-sell.html.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.